Back

Prasugrel-based de-escalation vs. conventional therapy after percutaneous coronary intervention in ACS patients according to the renal function

3 December 2022 (09:06 - 09:18)
Organised by:
Congress Presentation Part of: Late-Breaking Science Treatment ESC Professional Premium Access ESC Asia 2022 with APSC & AFC

About the speaker

Photo
Doctor Hyo-Soo Kim

Seoul National University Hospital, Seoul (Korea (Republic of))

2 More presentations in this session

Presentation thumbnail
The efficacy and safety of pulsed-field ablation in para-Hisian paroxysmal supraventricular tachycardia: first-in-human pilot trial
Doctor F. Li (Chengdu, CN)
Abstract Video
Presentation thumbnail
Multicenter registry of the Watchman left atrial appendage closure device for patients with atrial fibrillation in Japan: The TERMINATOR registry
Doctor T. Matsumoto (Kamakura, JP)
Abstract Video

Access the full session

Session thumbnail
Late-Breaking Science
Video

The Event

Event poster

ESC Asia 2022 with APSC & AFC

3 December 2022 09:06 CET
You may be interested in
thumbnail
Congress Presentation
Long-term outcomes of prasugrel-based de-escalation versus conventional therapy after PCI in ACS patients
1 September 2025
thumbnail
Congress Presentation
Renal function and intensive blood pressure lowering in high-risk adults without diabetes: insights from the Systolic Blood Pressure Intervention Trial (SPRINT)
3 September 2019
thumbnail
Congress Presentation
Acute kidney injury as a predictor of bleeding in ACS patients
29 June 2021
thumbnail
Congress Presentation
Impact of kidney function, ticagrelor and genetic polymorphism on high platelet reactivity
25 August 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources